首页> 外文期刊>Japanese journal of clinical oncology. >Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
【24h】

Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).

机译:S-1加顺铂同时放化疗在无法切除的局部晚期头颈部鳞状细胞癌患者中进行的II期临床试验:日本临床肿瘤学小组研究(JCOG0706)。

获取原文
获取原文并翻译 | 示例
           

摘要

A Phase II study was started in Japan to evaluate the efficacy and safety of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck. This study began in July 2008, and a total of 45 patients will be accrued from 13 institutions within 2 years. The primary endpoint is the clinical complete remission rate. The secondary endpoints are local progression-free survival, overall survival, progression-free survival, time to treatment failure, proportion of patients who achieve nutritional support-free survival and adverse events.
机译:日本开始了一项II期研究,以评估S-1加顺铂同时放化疗对无法切除的局部晚期头颈部鳞状细胞癌患者的疗效和安全性。这项研究于2008年7月开始,在2年内将在13个机构中招募45位患者。主要终点是临床完全缓解率。次要终点是局部无进展生存期,总体生存期,无进展生存期,治疗失败时间,获得无营养支持生存期和不良事件的患者比例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号